Souvie Biodelivery — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Souvie Biodelivery is an early-stage, private biotech founded in 2021, headquartered in Cambridge, USA, with a listed office in Tucson, Arizona. The company is developing a proprietary exosome-based drug delivery platform designed to target drugs to specific tissues, thereby improving therapeutic efficacy and minimizing side effects. Operating in the high-growth field of advanced drug delivery, Souvie is positioned to address a critical bottleneck in biopharma but remains at a pre-clinical, pre-revenue stage with no disclosed pipeline programs or funding. Its success hinges on validating its technology platform and securing partnerships or investment to advance toward clinical development.

Drug Delivery

Technology Platform

Engineered exosomes for tissue and site-specific delivery of active pharmaceutical ingredients (APIs). The platform aims to enhance biocompatibility, protect APIs from degradation, and improve targeting to reduce adverse drug reactions.

Opportunities

The global drug delivery market is vast and growing, with a strong need for technologies that improve drug safety and efficacy.

Souvie's exosome platform, if validated, could partner with pharmaceutical companies to enhance a wide range of therapeutic modalities, from small molecules to nucleic acids, across oncology, neurology, and other disease areas.

Risk Factors

The company faces significant technical risks in scaling exosome production and demonstrating reliable targeting, severe financial risk as an unfunded, pre-revenue startup, and intense competition from other well-funded exosome and nanoparticle delivery companies.

The lack of a disclosed management team also adds operational risk.

Competitive Landscape

Souvie operates in the competitive field of advanced drug delivery, competing directly with other exosome-focused biotechs like Evox Therapeutics and Codiak BioSciences, as well as companies developing lipid nanoparticles (LNPs), polymer conjugates, and other targeted delivery technologies. Success requires demonstrating clear differentiation in targeting, payload capacity, or manufacturability.

More companies in Drug Delivery & Formulation →More companies in United States →